GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare
29 September 2016
Issued: London, UK
GSK today announced that Brian McNamara, is appointed Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division effective immediately.
He succeeds Emma Walmsley who was last week appointed GSK CEO Designate succeeding Sir Andrew Witty as GSK CEO. In his new role, Brian will report to Andrew Witty until Emma becomes CEO. He will join GSK’s Corporate Executive Team effective immediately and will continue as a member of the Board of the Consumer Healthcare Joint Venture with Novartis. He will be based in the UK.
Brian is currently Head of Europe & Americas at GSK Consumer Healthcare. He joined GSK from Novartis following completion of GSK’s three-part transaction with Novartis and has been a member of GSK’s Consumer Healthcare Executive Team since 2015.
Prior to joining GSK, Brian spent eleven years at Novartis and sixteen years at Procter & Gamble.
Sir Andrew Witty, GSK CEO, said: “With his significant experience and expertise, Brian is the clear choice to build on the current momentum we are seeing in our business and fully maximise the future opportunities we have with our brands and to deliver the benefits of the integration.”
Brian McNamara said: “I am very excited about the opportunity to lead the Consumer Healthcare business at GSK. We have an amazing opportunity ahead of us to deliver on our promise to consumers and grow our business to further extend our position as a leading, global consumer healthcare company”.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015